7. Dauge ́ V., Kalivas P. W., Duffy T. and Roques B. P. (1992) Effect of inhibiting enkephalin catabolism in the VTA on motor
activity and extracellular dopamine. Brain Res. 599, 209–214.
8. Devine D. P., Leone P., Pocock D. and Wise R. A. (1993) Differential involvement of ventral tegmental mu, delta and kappa
opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J. Pharmac. exp. Ther.
226, 1236–1246.
9. Di Chiara G. and Imperato A. (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the
mesolimbic system of freely moving rats. Proc. natn. Acad. Sci. U.S.A. 85, 5274–5278.
10. Di Chiara G. and Imperato A. (1988) Opposite effects of mu and kappa opioid agonists on dopamine release in the nucleus
accumbens and dorsal caudate of freely moving rats. J. Pharmac. exp. Ther. 244, 1067–1080.
11. Erspamer V., Melchiorri P., Falconieri-Erspamer G., Negri L., Corsi R., Severini C., Barra D., Simmaco M. and Kreil G.
(1989) Deltorphins: a family of naturally occurring peptides with high affinity and selectivity for d opioid binding sites. Proc.
natn. Acad. Sci. U.S.A. 86, 5188–5192.
12. Fibiger H. L. (1982) Drugs and reinforcement mechanisms: a critical review of the catecholamine theory. A. Rev. Pharmac.
Toxicol. 18, 37–52.
13. Goldstein A. and Naidu A. (1989) Multiple opioid receptors: ligand selectivity profiles and binding site signatures. Molec.
Pharmac. 36, 265–272.
14. Hakan R. L. and Henriksen S. J. (1989) Opiate influences on nucleus accumbens neuronal electrophysiology: dopamine and
non-dopamine mechanisms. J. Neurosci. 9, 3538–3546.
15. Handa B. K., Lane A. C., Lord J. A. H., Morgan B. A., Rance M. J. and Smith C. F. C. (1981) Analogues of b-LPH61-64
possessing selective agonist activity at m-opiate receptors. Eur. J. Pharmac. 70, 531–540.
16. Hruby V. J. and Gehrig C. A. (1989) Recent developments in the design of receptor specific opioid peptides. Med. Res. Rev. 9,
343–401.
17. Johnson D. W. and Glick S. D. (1993) Dopamine release and metabolism in nucleus accumbens and striatum of morphinetolerant and nontolerant rats. Pharmac. Biochem. Behav. 46, 341–347.
18. Kalivas P. W., Wilderlow E., Stanley D., Breese G. and Prange A. J. (1983) Enkephalin action on the mesolimbic system: a
dopamine-dependent and a dopamine-independent increase in locomotor activity. J. Pharmac. exp. Ther. 227, 229–237.
19. Koob G. F. and Bloom F. E. (1988) Cellular and molecular mechanisms of drug dependence. Science 242, 715–723.
20. Kosterlitz H. W. (1985) The Wellcome Foundation Lecture, 1982. Opioid peptides and their receptors. Proc. R. Soc. Lond. 225,
27–40.
21. Kramer T. H., Shook J. E., Kazmierski W., Ayres E. A., Wire W. S., Hruby V. J. and Burks T. F. (1989) Novel peptidic mu
opioid antagonists: pharmacologic characterization in vitro and in vivo. J. Pharmac. exp. Ther. 249, 544–551.
22. Kreil G., Barra D., Simmaco M., Erspamer V., Erspamer G. F., Negri L., Severini C., Corsi R. and Melchiorri P. (1989)
Deltorphin, a novel amphibian skin peptide with high selectivity and affinity for delta opioid receptors. Eur. J. Pharmac. 162,
123–128.
23. Latimer L. G., Duffy P. and Kalivas P. W. (1987) Mu opioid receptor involvement in enkephalin activation of dopamine
neurons in the ventral tegmental area. J. Pharmac. exp. Ther. 241, 328–337.
24. Lee P. H., McNutt R. W. and Chang K.-J. (1993) A nonpeptidic delta opioid receptor agonist, BW373U86, attenuates the
development and expression of morphine abstinence precipitated by naloxone in rat. J. Pharmac. exp. Ther. 267, 883–887.
25. Leone P., Pocock D. and Wise R. A. (1991) Morphine–dopamine interaction: ventral tegmental morphine increase nucleus
accumbens dopamine release. Pharmac. Biochem. Behav. 39, 469–472.
26. Lindefors N., Amberg G. and Ungerstedt U. (1989) Intracerebral microdialysis, I. Experimental studies of diffusion kinetics. J.
pharmac. Meth. 22, 141–156.
27. Longoni R., Spina L., Mulas A., Carboni E., Garau L., Melchiorri P. and Di Chiara G. (1991) (D-Ala2) Deltorphine II: D1- dependent stereotypies and stimulation of dopamine release in the nucleus accumbens. J. Neurosci. 11, 1565–1576.
28. Maguire P., Tsai N., Kamal J., Cometta-Morini C., Upton C. and Loew G. (1992) Pharmacological profiles of fentanyl analogs
at m, d and k opiate receptors. Eur. J. Pharmac. 231, 219–225.
29. Maisonneuve I. M., Keller R. W. Jr and Glick S. D. (1991) Interactions between ibogaine, a potential anti-addictive agent and
morphine: an in vivo microdialysis study. Eur. J. Pharmac. 199, 35–42.
30. Mansour A., Khachaturian H., Lewis M. E., Akil H. and Watson S. J. (1987) Autoradiographic differentiation of mu, delta, and
kappa opioid receptors in the rat forebrain and midbrain. J. Neurosci. 7, 2445–2464.
31. Mosberg H. L., Hurst R., Hruby V. J., Yamamura H. I., Galligan J. J. and Burks T. F. (1983) Bis-penicillamine enkephalins
possess highly improved specificity towards opioid receptors. Proc. natn. Acad. Sci. U.S.A. 80, 5871–5874.
32. Murai T., Koshikawa N., Kanayama T., Takada K., Tomiyama K. and Kobayashi M. (1994) Opposite effects of midazolam and
b-carboline-3-carboxylate ethyl ester on the release of dopamine from rat nucleus accumbens measured by in vivo microdialysis. Eur. J. Pharmac. 261, 65–71.
33. Narita M., Suzuki T., Funada M., Misawa M. and Nagase H. (1993) Involvement of d-opioid receptors in the effects of
morphine on locomotor activity and the mesolimbic dopaminergic system in mice. Psychopharmacology, Berlin 111, 423–426.
34. Nestler E. J. (1992) Molecular mechanisms of drug addiction. J. Neurosci. 12, 2439–2450.
35. O'Neill S. T., Collins M. A., Pettit H. O., McNutt R. W. and Chang K.-J. (1997) Antagonistic modulation between the delta
opioid agonist BW373U86 and the mu opioid agonist fentanyl in mice. J. Pharmac. exp. Ther. 282, 271–277.
36. Parry T. J., Carter T. L. and McElligott J. G. (1990) Physical and chemical considerations in the in vitro calibration of
microdialysis probes for biogenic amine neurotransmitters and metabolites. J. Neurosci. Meth. 323, 175–183.
37. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic, New York.
38. Pelton J. T., Kazmierski W., Gulya K., Yamamura H. I. and Hruby V. J. (1986) Design and synthesis of conformationally
constrained somatostatin analogues with high potency and specificity for m opioid receptors. J. med. Chem. 29, 2370–2375.
39. Pentney R. J. W. and Gratton A. (1991) Effects of local delta and mu opioid receptor activation on basal and stimulated
dopamine release in striatum and nucleus accumbens of rat: an in vivo electrochemical study. Neuroscience 45, 95–102.
40. Petit F., Hamon M., Fournie-Zaluski M. C., Roques B. P. and Glowinski J. (1986) Further evidence for a role of d-opiate
receptors in the presynaptic regulation of newly synthesized dopamine release. Eur. J. Pharmac. 126, 1–9.
41. Portoghese P. S. (1991) An approach to the design of receptor-type-selective non-peptide antagonists of peptidergic receptors:
d opioid antagonists. J. med. Chem. 346, 1757–1762.
42. Portoghese P. S., Nagase H., MaloneyHuss K. E., Lin C. E. and Takemori A. E. (1991) Role of spacer and address components
in peptidomimetic d opioid receptor antagonists related to naltrindole. J. med. Chem. 34, 1715–1720.
